Table 1.  Clinical features of type 2 diabetes patients with or without the S20G mutation of the islet amyloid polypeptide gene at final analysis.

	Non‐S20G‐T2D‐patients (n = 70)	S20G‐patients (individual)
		#1	#2	#3	#4	#5	#6	Mean
Sex	Female; 34	Female	Male	Female	Male	Male	Male	Female; 2
Age at diagnosis (years)	43.3 ± 11.7	49	38	13	30	48	22	33.3 ± 14.3
Duration of diabetes (years)	23.7 ± 9.1	29	36	27	45	18	22	29.7 ± 9.8
BMI (kg/m2)	23.2 ± 3.7	21.4	26.0	20.2	22.3	28.7	22.3	23.5 ± 3.2
Final A1c (%)	7.7 ± 0.9	8.7	8.3	7.1	8.3	12.5	7.7	8.8 ± 1.9
Follow‐up interval (years)	18.1 ± 5.2	25	23	26	21	5	5	17.5 ± 9.8
Duration from diagnosis to the beginning of insulin therapy (years)	(See Figure 2)	7	14	9	30	12	17	14.8 ± 3.4
Family history of diabetes (+, positive)	Positive; 42	+	+	+	+	+	+	Positive; 6

Non‐S20G‐T2D‐patients, type 2 diabetes patients without the S20G mutation of the islet amyloid polypeptide gene (IAPP); S20G‐patients, type 2 diabetic patients with the S20G mutation of the IAPP gene. BMI, body mass index.